Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions

Ashay Bhatwadekar, E. P. Guerin, Yagna P R Jarajapu, Sergio Caballero, Carl Sheridan, David Kent, Laurence Kennedy, M. Cecilia Lansang, Frank W. Ruscetti, Carl J. Pepine, Paul J. Higgins, Stephen H. Bartelmez, Maria B. Grant

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE - Peripheral blood CD34+ cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-β, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-β1 inhibition in CD34+ cells would improve their reparative ability. RESEARCH DESIGN AND METHODS - To inhibit TGF-β1 protein expression, CD34+ cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-β1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability. RESULTS - TGF-β1-PMO treatment of diabetic CD34+ cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34+ cells to injured acellular retinal capillaries was greater after TGF-β1-PMO treatment compared with control PMO-treated cells. CONCLUSIONS - Transient inhibition of TGF-β1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34+ cells.

Original languageEnglish (US)
Pages (from-to)2010-2019
Number of pages10
JournalDiabetes
Volume59
Issue number8
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Transforming Growth Factors
Blood Vessels
Nitric Oxide
Intercellular Signaling Peptides and Proteins
Morpholinos
Retinal Vessels
Stem Cell Factor
Reperfusion Injury
Biological Availability
Blood Cells
Cell Survival
Research Design
Therapeutics
Survival
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bhatwadekar, A., Guerin, E. P., Jarajapu, Y. P. R., Caballero, S., Sheridan, C., Kent, D., ... Grant, M. B. (2010). Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions. Diabetes, 59(8), 2010-2019. https://doi.org/10.2337/db10-0287

Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions. / Bhatwadekar, Ashay; Guerin, E. P.; Jarajapu, Yagna P R; Caballero, Sergio; Sheridan, Carl; Kent, David; Kennedy, Laurence; Lansang, M. Cecilia; Ruscetti, Frank W.; Pepine, Carl J.; Higgins, Paul J.; Bartelmez, Stephen H.; Grant, Maria B.

In: Diabetes, Vol. 59, No. 8, 08.2010, p. 2010-2019.

Research output: Contribution to journalArticle

Bhatwadekar, A, Guerin, EP, Jarajapu, YPR, Caballero, S, Sheridan, C, Kent, D, Kennedy, L, Lansang, MC, Ruscetti, FW, Pepine, CJ, Higgins, PJ, Bartelmez, SH & Grant, MB 2010, 'Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions', Diabetes, vol. 59, no. 8, pp. 2010-2019. https://doi.org/10.2337/db10-0287
Bhatwadekar, Ashay ; Guerin, E. P. ; Jarajapu, Yagna P R ; Caballero, Sergio ; Sheridan, Carl ; Kent, David ; Kennedy, Laurence ; Lansang, M. Cecilia ; Ruscetti, Frank W. ; Pepine, Carl J. ; Higgins, Paul J. ; Bartelmez, Stephen H. ; Grant, Maria B. / Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions. In: Diabetes. 2010 ; Vol. 59, No. 8. pp. 2010-2019.
@article{7ca11ac2fb8e43149c21df0914b214f4,
title = "Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions",
abstract = "OBJECTIVE - Peripheral blood CD34+ cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-β, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-β1 inhibition in CD34+ cells would improve their reparative ability. RESEARCH DESIGN AND METHODS - To inhibit TGF-β1 protein expression, CD34+ cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-β1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability. RESULTS - TGF-β1-PMO treatment of diabetic CD34+ cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34+ cells to injured acellular retinal capillaries was greater after TGF-β1-PMO treatment compared with control PMO-treated cells. CONCLUSIONS - Transient inhibition of TGF-β1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34+ cells.",
author = "Ashay Bhatwadekar and Guerin, {E. P.} and Jarajapu, {Yagna P R} and Sergio Caballero and Carl Sheridan and David Kent and Laurence Kennedy and Lansang, {M. Cecilia} and Ruscetti, {Frank W.} and Pepine, {Carl J.} and Higgins, {Paul J.} and Bartelmez, {Stephen H.} and Grant, {Maria B.}",
year = "2010",
month = "8",
doi = "10.2337/db10-0287",
language = "English (US)",
volume = "59",
pages = "2010--2019",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Transient inhibition of transforming growth factor-β1 in human diabetic CD34+ cells enhances vascular reparative functions

AU - Bhatwadekar, Ashay

AU - Guerin, E. P.

AU - Jarajapu, Yagna P R

AU - Caballero, Sergio

AU - Sheridan, Carl

AU - Kent, David

AU - Kennedy, Laurence

AU - Lansang, M. Cecilia

AU - Ruscetti, Frank W.

AU - Pepine, Carl J.

AU - Higgins, Paul J.

AU - Bartelmez, Stephen H.

AU - Grant, Maria B.

PY - 2010/8

Y1 - 2010/8

N2 - OBJECTIVE - Peripheral blood CD34+ cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-β, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-β1 inhibition in CD34+ cells would improve their reparative ability. RESEARCH DESIGN AND METHODS - To inhibit TGF-β1 protein expression, CD34+ cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-β1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability. RESULTS - TGF-β1-PMO treatment of diabetic CD34+ cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34+ cells to injured acellular retinal capillaries was greater after TGF-β1-PMO treatment compared with control PMO-treated cells. CONCLUSIONS - Transient inhibition of TGF-β1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34+ cells.

AB - OBJECTIVE - Peripheral blood CD34+ cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-β, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-β1 inhibition in CD34+ cells would improve their reparative ability. RESEARCH DESIGN AND METHODS - To inhibit TGF-β1 protein expression, CD34+ cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-β1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability. RESULTS - TGF-β1-PMO treatment of diabetic CD34+ cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34+ cells to injured acellular retinal capillaries was greater after TGF-β1-PMO treatment compared with control PMO-treated cells. CONCLUSIONS - Transient inhibition of TGF-β1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34+ cells.

UR - http://www.scopus.com/inward/record.url?scp=77955369930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955369930&partnerID=8YFLogxK

U2 - 10.2337/db10-0287

DO - 10.2337/db10-0287

M3 - Article

C2 - 20460428

AN - SCOPUS:77955369930

VL - 59

SP - 2010

EP - 2019

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -